Jian Zhou

ORCID: 0000-0002-9917-5622
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Liver Disease Diagnosis and Treatment
  • Gallbladder and Bile Duct Disorders
  • Pancreatic and Hepatic Oncology Research
  • Liver Disease and Transplantation
  • Acute Myeloid Leukemia Research
  • Cancer, Hypoxia, and Metabolism
  • Hepatitis B Virus Studies
  • Galectins and Cancer Biology
  • Glycosylation and Glycoproteins Research
  • Hematopoietic Stem Cell Transplantation
  • Ferroptosis and cancer prognosis
  • Cancer Mechanisms and Therapy
  • Cancer Research and Treatments
  • Viral-associated cancers and disorders
  • Immunodeficiency and Autoimmune Disorders
  • Glioma Diagnosis and Treatment
  • Medical Imaging Techniques and Applications
  • Advanced X-ray and CT Imaging
  • Cancer-related molecular mechanisms research
  • RNA modifications and cancer
  • Cancer, Lipids, and Metabolism
  • Chronic Myeloid Leukemia Treatments
  • Radiomics and Machine Learning in Medical Imaging

Fudan University
2007-2025

Zhongshan Hospital
2008-2025

Sun Yat-sen University
2011-2025

Cancer Institute (WIA)
2008-2025

The First Affiliated Hospital, Sun Yat-sen University
2011-2025

Henan Cancer Hospital
2019-2024

Zhengzhou University
2019-2024

Shanghai Electric (China)
2023-2024

Sun Yat-sen University Cancer Center
2019-2024

State Key Laboratory of Oncology in South China
2022-2024

Abstract Hepatocellular carcinoma (HCC) is an aggressive cancer with a poor prognosis. The role of autophagy and the prognostic value autophagic genes are largely unknown in HCC. Here, we showed decreased expression their corresponding activity increased antiapoptotic gene Bcl-xL HCC cell lines compared normal hepatic line. We also found Beclin 1 44 tissue samples adjacent nontumor tissues. In addition, that most malignant tissues recurrent disease displayed much lower levels, especially...

10.1158/0008-5472.can-08-1573 article EN Cancer Research 2008-11-14

Understanding the roles of mammalian autophagy in cancer highlights recent advances pharmacologic manipulation autophagic pathways as a therapeutic strategy for cancer. However, status and corresponding functions hepatocellular carcinoma (HCC) after stress remain to be clarified. This study was determine whether machinery could activated chemotherapy contribution tolerance oxaliplatin HCC.Autophagy activation cell death induced by were examined two HCC lines well vivo using an model nude...

10.1158/1078-0432.ccr-11-0816 article EN Clinical Cancer Research 2011-08-09

Abstract Purpose: Cytokeratin 10 (CK10) was found to be expressed differently in human hepatocellular carcinoma (HCC) cell lines with different metastatic potentials our previous research. The aim of this study assess the value CK10 alone or combination cytokeratin 19 (CK19) predicting tumor recurrence after curative resection HCC patients. Experimental Design: expression stepwise and tissues from 50 patients investigated using immunofluorescence assay, quantitative real-time reverse...

10.1158/1078-0432.ccr-07-4338 article EN Clinical Cancer Research 2008-06-15

To investigate the role of CD24 in tumor invasion and prognostic significance hepatocellular carcinoma (HCC).CD24 expression was measured stepwise metastatic HCC cell lines, tumor, peritumoral tissues, normal liver tissues by quantitative real-time PCR Western blot. The investigated depletion using small interfering RNA. Tumor tissue microarrays 314 patients who underwent resection between 1997 2000 were used to detect CD24, beta-catenin, proliferating nuclear antigen. Prognostic assessed...

10.1158/1078-0432.ccr-09-0151 article EN Clinical Cancer Research 2009-08-26

OBJECTIVE Moyamoya disease (MMD) is a rare, genetically heterogeneous cerebrovascular disease. The authors conducted genetic study of really interesting new gene (RING) finger protein 213 ( RNF213); actin alpha 2 ACTA2); BRCA1/BRCA2-containing complex subunit 3 BRCC3); and guanylate cyclase 1, soluble, GUCY1A3) as well clinical phenotype analysis in Chinese MMD patients to determine whether differences are responsible for the different features that appear ethnicities. METHODS A panel was...

10.3171/2016.2.jns152173 article EN Journal of neurosurgery 2016-04-29

Gallbladder cancer (GBC) is the most common and lethal malignancy of biliary tract that lacks effective therapy. In many GBC cases, infiltration into adjacent organs or distant metastasis happened long before diagnosis, especially direct liver invasion, which unfavorable way spreading. Single-cell RNA sequencing (scRNA-seq), spatial transcriptomics (ST), proteomics, multiplexed immunohistochemistry (mIHC) were performed on across multiple tumor stages to characterize microenvironment (TME),...

10.1186/s40164-024-00521-7 article EN cc-by Experimental Hematology and Oncology 2024-05-31

Background and Aims: Cystatin B (CSTB) has been demonstrated to play a significant role in the pathogenesis of number diseases, including evolution progression multiple cancers. Nevertheless, function CSTB intrahepatic cholangiocarcinoma (iCCA) is yet be fully elucidated. Methods: By analyzing transcriptome sequencing data from FU-iCCA cohort, iCCA-27 three public databases, we identified genes associated with iCCA prognosis selected as subject our study. The expression was examined between...

10.3390/curroncol32020056 article EN cc-by Current Oncology 2025-01-21

Neoadjuvant therapy (NAT) is increasingly used to treat patients with initially unresectable intrahepatic cholangiocarcinoma (iCCA). A histopathologic grading system for residual tumors that can predict patient survival lacking in the literature. This retrospective study enrolled 151 iCCA who received NAT. The percentage of viable tumor (%RVT) extent was calculated by RVT surface area/total bed area ×100 and scored 5% increments. Kaplan-Meier Cox regression analyses were investigate its...

10.1097/pas.0000000000002359 article EN cc-by-nc-nd The American Journal of Surgical Pathology 2025-03-19

Sorafenib, a multikinase inhibitor, is new standard treatment for patients with advanced hepatocellular carcinoma (HCC).However, resistance to this regimen frequently observed in clinical practice, and the molecular basis of remains largely unknown.Herein, antitumor activity sorafenib was assessed 16 patient-derived xenograft (PDX) models HCC.Gene expression analysis conducted identify factors that promote resistance.Quantitative RT-PCR immunoblotting were used determine gene activation...

10.7150/jca.31448 article EN cc-by-nc Journal of Cancer 2019-01-01

Comorbidity among cancer patients is prevalent and influential to prognosis after operation. Limited data are available on comorbidity evaluations in with intrahepatic cholangiocarcinoma (ICC). This study aimed assess the distribution ICC adapt Charlson Index (CCI) or age-adjusted CCI (ACCI) for survival prediction.The cohort included 268 treated curative surgery from January 2000 December 2007 at Department of Liver Surgery, Zhongshan Hospital. The association between index overall (OS)...

10.21037/atm.2020.03.23 article EN Annals of Translational Medicine 2020-04-01

Abstract Biological evidence suggests that vitamin D has numerous anticancer functions, but the associations between status and colorectal cancer (CRC) risk survival remain inconclusive. Based on UK Biobank, we prospectively evaluated of season‐standardized 25‐hydroxyvitamin (25(OH)D) concentrations with CRC among 360 061 participants, 2509 cases. We observed an inverse linear relationship 25(OH)D ( P for linearity = .01; HR per 1‐SD increment, 0.95; 95% CI, 0.91‐0.99). Compared to lowest...

10.1002/ijc.33580 article EN International Journal of Cancer 2021-03-30

Liver-intestine cadherin (LI-cadherin; CDH-17) is a new member of the superfamily with distinct structural and functional features. The study was designed to investigate role LI-cadherin in tumor invasion prognosis human hepatitis B virus (HBV)-positive hepatocellular carcinoma (HCC).LI-cadherin expression HBV-positive cell lines low- high-invasive potentials evaluated by Western-blot, immunofluorescence, real-time polymerase chain reaction (PCR) analyses. also vitro small-interfering...

10.1002/cncr.24513 article EN Cancer 2009-07-22

The purpose of this study was to investigate the efficacy and safety drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Chinese hepatocellular carcinoma (HCC) patients prognostic factors for response as well survival. A total 275 HCC were included prospective study. Treatment assessed by modified Response Evaluation Criteria Solid Tumors (mRECIST), progression-free survival (PFS) overall (OS) determined. Liver function adverse events (AEs) before after DEB-TACE...

10.3727/096504019x15662966719585 article EN cc-by-nc-nd Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2019-09-27

Abstract Background Hepatocellular carcinoma (HCC) ranks as the third most common cause of cancer related death globally, representing a substantial challenge to global healthcare systems. In China, primary risk factor for HCC is hepatitis B virus (HBV). Aberrant serum glycoconjugate levels have long been linked progression HBV-associated (HBV-HCC). Nevertheless, few study systematically explored dysregulation glycoconjugates in and their potency diagnostic prognostic biomarker. Methods An...

10.1186/s12964-024-01569-y article EN cc-by Cell Communication and Signaling 2024-04-01

6044 Background: Consensus on neoadjuvant treatment strategies for resectable head and neck squamous cell carcinoma (HNSCC) is not proposed currently. Preclinical clinical findings suggested that PD-1/CTLA-4 bispecific antibodies may have synergistic anti-tumor activity. This study aimed to explore the safety activity of cadonilimab in combination with platinum-based dual-drug chemotherapy locally advanced, HNSCC. Methods: In this open-label phase II trial, eligible patients untreated HNSCC...

10.1200/jco.2024.42.16_suppl.6044 article EN Journal of Clinical Oncology 2024-06-01

Background & Aims: Adjuvant therapies for hepatocellular carcinoma (HCC) such as interferon-alpha are effective only in a subset of patients.Previously we found that HCC patients with low level miR-26 have survival benefits from interferon-alpha.The purpose this study is to develop standardized diagnostic test (referred MIR26-DX) assist identification candidate adjuvant therapy.Methods: We developed multiplex reverse-transcription quantitative polymerase-chain-reaction assay determine the...

10.7150/ijbs.6214 article EN cc-by-nc International Journal of Biological Sciences 2013-01-01

This study aimed to investigate the efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization (DEB-TACE) in treating Chinese patients with liver cancer. A total 367 cancer from 24 medical centers were consecutively enrolled this multiple-center, prospective cohort study, including 275 hepatocellular carcinoma (HCC) cases, 37 intrahepatic cholangiocarcinoma (ICC) 55 secondary cases. All received CalliSpheres ® DEB-TACE treatment. Treatment response,...

10.3727/096504019x15766663541105 article EN cc-by-nc-nd Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2019-12-20

Abstract Aims TANK‐binding kinase 1 (TBK1) is involved in regulating the pathological process of a variety inflammatory diseases central nervous system. However, its role and underlying molecular mechanisms spinal cord injury (SCI) remain largely unknown. Methods We employed TBK1 inhibitor amlexanox (ALX) to address this question. An vivo clip‐compressive SCI model vitro lipopolysaccharide (LPS)‐induced astrocyte inflammation were established examine effects inhibition on expression...

10.1111/cns.14170 article EN cc-by CNS Neuroscience & Therapeutics 2023-04-10

Abstract This study aimed to investigate the efficacy and safety of drug-eluting beads (DEB) transarterial chemoembolization (TACE) treatment in Chinese intrahepatic cholangiocarcinoma (ICC) patients. 37 ICC patients underwent DEB-TACE CTILC (registered on clinicaltrials.gov with registry No. NCT03317483) were included this present study. Treatment response was assessed according modified Response Evaluation Criteria Solid Tumors (mRECIST). Overall survival (OS) calculated from time...

10.1097/md.0000000000019276 article EN cc-by-nc Medicine 2020-03-01

It is no consensus on the best management for patients with large hepatic hemangiomas. This study was designed to evaluate efficacy and safety of percutaneous sclerotherapy compared surgical resection hemangiomas.A total 89 hemangiomas from single center underwent either (n = 14) or 75) as first-line treatment retrospectively studied, followed up 9-24 months using ultrasound. Terms intraoperative postoperative information, complications, effectiveness were between two groups.Percutaneous had...

10.1186/s12893-022-01574-3 article EN cc-by BMC Surgery 2022-04-07
Coming Soon ...